Lung cancer
Conditions
Interventions
Rivaroxaban group:Rivaroxaban+Tislelizumab+chemotherapy
Low molecular weight heparin group:Low molecular weight heparin++Tislelizumab+chemotherapy
Control group:Tislelizumab+chemotherapy
Sponsors
Dianjiang People’s Hospital of Chongqing
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Histologically confirmed advanced non-small cell lung cancer with TNM stage IIIB--IV, no indication for surgery; 2. Measurable or evaluable disease and imaging evidence; 3. No other therapy prior to the study protocol ; 4. Good general condition; There was no severe heart, liver and kidney dysfunction; 5. Gene mutation detection was performed to determine the patient's gene mutation status, and EGFR/ALK negative patients were selected; 6. Karnofsky performance status (KPS) >=60 points; 7. Patients agreed to be enrolled in the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. bone marrow hematopoietic function injury; 2. patients with allergic constitution or allergy to multiple drugs; 3. in the process of clinical medication, poor compliance affects the efficacy evaluators; 4. severe complications occurred during the treatment and it was not suitable to continue the treatment; 5. previous history of thrombosis; 6. patients with active bleeding, including central nervous system bleeding, intracranial or spinal high-risk bleeding lesions, active bleeding, and chronic clinically significant bleeding; 7. patients with bleeding tendency, including thrombocytopenia (platelet <50×10^9/L), severe platelet dysfunction (uremia, drug use, aplastic anemia), coagulation disorders, coagulation factor abnormalities (such as factor ? deficiency, severe liver disease); 8. disseminated Intravascular Coagulation (DIC); 9. patients with acute venous thrombosis; 10. receiving other anticoagulant therapy; 11. patients with long-term oral aspirin or clopidogrel due to underlying diseases; 12. patients with thrombosis on admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective remission rate;Disease control rate;Overall survival time;Adverse reaction;Quality of life; | — |
Countries
China
Contacts
Public ContactHongchuan Zhang
Dianjiang People’s Hospital of Chongqing
Outcome results
None listed